John Rogers' Strategic Moves: A Closer Look at Norwegian Cruise Line Holdings Ltd

John Rogers (Trades, Portfolio) recently submitted the 13F filing for the first quarter of 2025, providing insights into his investment moves during this period. John Rogers (Trades, Portfolio) founded Ariel Investment, LLC in 1983. Rogers manages Ariel's small and mid-cap institutional portfolios as well as the Ariel Fund (ARGFX) and Ariel Appreciation Fund (CAAPX). He is also a long-term Forbes columnist writing a column called "Patient Investor." Rogers has concentrated his investment selection on small and medium-sized companies whose share prices are undervalued. He believes that patience, independent thinking, and a long-term outlook are essential to achieving good returns. His fund seeks to purchase companies whose characteristics include high barriers to entry, sustainable competitive advantages, and predictable fundamentals that allow for double-digit cash earnings growth. Rogers purchases companies when they are trading at a low valuation relative to potential earnings (p/e less than 13x forward cash earnings) and/or a low valuation relative to intrinsic worth (40% discount to private market value).
Warning! GuruFocus has detected 6 Warning Sign with UBER.
John Rogers (Trades, Portfolio) added a total of 5 stocks, among them:
The most significant addition was Algonquin Power & Utilities Corp (NYSE:AQN), with 6,952,341 shares, accounting for 0.42% of the portfolio and a total value of $35.73 million.
The second largest addition to the portfolio was Owens-Corning Inc (NYSE:OC), consisting of 112,578 shares, representing approximately 0.19% of the portfolio, with a total value of $16.08 million.
The third largest addition was Vanguard Total World Stock ETF (VT), with 74,824 shares, accounting for 0.1% of the portfolio and a total value of $8.68 million.
John Rogers (Trades, Portfolio) also increased stakes in a total of 48 stocks, among them:
The most notable increase was Norwegian Cruise Line Holdings Ltd (NYSE:NCLH), with an additional 5,077,531 shares, bringing the total to 9,081,170 shares. This adjustment represents a significant 126.82% increase in share count, a 1.13% impact on the current portfolio, with a total value of $172.18 million.
The second largest increase was OneSpaWorld Holdings Ltd (NASDAQ:OSW), with an additional 2,932,284 shares, bringing the total to 10,713,305. This adjustment represents a significant 37.69% increase in share count, with a total value of $179.88 million.
John Rogers (Trades, Portfolio) completely exited 9 of the holdings in the first quarter of 2025, as detailed below:
Royal Caribbean Group (NYSE:RCL): John Rogers (Trades, Portfolio) sold all 457,908 shares, resulting in a -1.13% impact on the portfolio.
DaVita Inc (NYSE:DVA): John Rogers (Trades, Portfolio) liquidated all 235,058 shares, causing a -0.38% impact on the portfolio.
John Rogers (Trades, Portfolio) also reduced positions in 49 stocks. The most significant changes include:
Reduced Check Point Software Technologies Ltd (NASDAQ:CHKP) by 459,120 shares, resulting in a -40.4% decrease in shares and a -0.91% impact on the portfolio. The stock traded at an average price of $211.9 during the quarter and has returned -2.70% over the past 3 months and 15.75% year-to-date.
Reduced The Goldman Sachs Group Inc (NYSE:GS) by 108,472 shares, resulting in a -92.33% reduction in shares and a -0.66% impact on the portfolio. The stock traded at an average price of $601.74 during the quarter and has returned -6.30% over the past 3 months and 8.09% year-to-date.
At the first quarter of 2025, John Rogers (Trades, Portfolio)'s portfolio included 106 stocks, with top holdings including 3.16% in Mattel Inc (NASDAQ:MAT), 3.02% in Jones Lang LaSalle Inc (NYSE:JLL), 2.99% in Madison Square Garden Entertainment Corp (NYSE:MSGE), 2.86% in Lazard Inc (NYSE:LAZ), and 2.85% in First American Financial Corp (NYSE:FAF).
The holdings are mainly concentrated in 11 industries: Financial Services, Consumer Cyclical, Industrials, Healthcare, Communication Services, Technology, Consumer Defensive, Real Estate, Energy, Basic Materials, and Utilities.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Upturn

26 minutes ago

• Business Upturn

European Medicines Agency Recommends Market Approval of AVT06, Alvotech's Proposed Biosimilar to Eylea® (aflibercept)

REYKJAVIK, Iceland and LONDON, June 23, 2025 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human use (CHMP) adopted a positive opinion recommending approval for AVT06, Alvotech's proposed biosimilar to Eylea® (aflibercept 2 mg). Based on a positive recommendation by CHMP, biosimilar medicines can be approved by the European Commission for marketing in the European Economic Area, that includes the 27 member states of the European Union, in addition to Norway, Iceland and Lichtenstein. 'CHMP's positive opinion takes us a step closer to being able to market our proposed biosimilar in Europe, which is excellent news for patients and their caregivers. Alvotech looks forward to increasing access to this vital biologic treatment for eye disorders,' said Joseph McClellan, Chief Scientific Officer of Alvotech. Advertisement 'We are pleased with the CHMP's positive opinion, which marks an important milestone in our mission to bring high-quality, specialist medicines to patients across Europe,' said Nick Warwick, Chief Medical Officer of Advanz Pharma. The CHMP opinion recommends granting of a marketing authorization for AVT06 intended for the treatment of adults with neovascular (wet) age-related macular degeneration (AMD), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), visual impairment due to diabetic macular oedema (DME) and visual impairment due to myopic choroidal neovascularisation (myopic CNV). Alvotech is responsible for the development and commercial supply of the proposed biosimilar. Advanz Pharma is responsible for registration and has exclusive commercialization rights for most countries in Europe. In 2024, global sales of Eylea® were about US$9 billion, and one third of these sales were in Europe [1]. In January 2024 Alvotech announced positive top-line results from a confirmatory clinical study with AVT06 (AVT06-GL-C01) comparing the efficacy, safety, and immunogenicity of the proposed biosimilar to Eylea® in patients with neovascular (wet) AMD. The study met its primary endpoint, with results demonstrating therapeutic equivalence between Alvotech's biosimilar candidate and Eylea® [2]. Alvotech is also developing AVT29, a proposed biosimilar to Eylea® HD, a higher dose (aflibercept 8 mg) aflibercept. Advanz has licensed the distribution rights from Alvotech for both biosimilar candidates, for the same territory. About AVT06 (aflibercept) AVT06 is a recombinant fusion protein and a biosimilar candidate to Eylea® (aflibercept), which binds vascular endothelial growth factors (VEGF), inhibiting the binding and activation of VEGF receptors, neovascularization, and vascular permeability [3]. AVT06 is an investigational product and has not received regulatory approval in any country. Biosimilarity has not been established by regulatory authorities and is not claimed. Sources [1] Global Data and IQVIA [2] Agostini, H. (2025). A randomized, double-masked parallel-group, multicenter clinical study evaluating the efficacy and safety of the biosimilar candidate AVT06 compared to the reference product aflibercept in participants with neovascular age-related macular degeneration. Expert Opinion on Biological Therapy, 1–15. [3] Use of trademarks Elyea® is a registered trademark of Regeneron Pharmaceuticals Inc. and Bayer AG. About Alvotech Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech's current pipeline includes eight disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech's commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit . None of the information on the Alvotech website shall be deemed part of this press release. About Advanz Pharma Partner of choice in specialty, hospital, and rare disease medicines. Advanz Pharma is a global pharmaceutical company with the purpose to improve patients' lives by providing and enhancing the specialty, hospital, and rare disease medicines they depend on. Our headquarters are in London, UK. We have commercial sales in more than 90 countries globally and have a direct commercial presence in more than 20 countries, including key countries in Europe, the US, Canada, and Australia, a Centre of Excellence in Mumbai, India, as well as an established global distribution and commercialization partner network. Advanz Pharma's product portfolio and pipeline comprises innovative medicines, biosimilars & specialty generics, and originator brands. Our products cover a broad range of therapeutic areas, including hepatology, rheumatology, gastroenterology, anti-infectives, critical care, endocrinology, oncology, CNS, and, more broadly, rare disease medicines. Our ambition is to be a partner of choice for the commercialization of specialty, hospital, and rare disease medicines in Europe, Canada, and Australia. In line with our ambition, we are partnering with biopharma and development companies to bring medicines to patients. We can only achieve this due to our dedicated and highly qualified employees, acting in line with our company values of entrepreneurship, speed, and integrity. Alvotech Forward Looking Statements Certain statements in this communication may be considered 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements generally relate to future events or the future financial or operating performance of Alvotech and may include, for example, Alvotech's expectations regarding future growth, results of operations, performance, future capital and other expenditures, competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, results, level of activities, performance, goals or achievements or other future events, regulatory review and interactions, the satisfactory responses to the FDA's inspection findings and resolution of other deficiencies conveyed following the re-inspection of Alvotech's manufacturing site, the potential approval, including for AVT02, AVT04, and the product candidates in scope of the partnership with Advanz, by the FDA and other regulatory agencies and commercial launch of its product candidates, the timing of the announcement of clinical study results, the commencement of patient studies, regulatory applications, approvals and market launches, and the estimated size of the total addressable market of Alvotech's pipeline products. In some cases, you can identify forward-looking statements by terminology such as 'may', 'should', 'expect', 'intend', 'will', 'estimate', 'anticipate', 'believe', 'predict', 'potential' or 'continue', or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech's control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) the ability to reach development milestones under commercial partnership agreements including the partnership with Advanz; (2) the ability to raise substantial additional funding, which may not be available on acceptable terms or at all; (3) the ability to maintain stock exchange listing; (4) changes in applicable laws or regulations; (5) the possibility that Alvotech may be adversely affected by other economic, business, and/or competitive factors; (6) Alvotech's estimates of expenses and profitability; (7) Alvotech's ability to develop, manufacture and commercialize the products and product candidates in its pipeline; (8) the ability of Alvotech or its partners to respond to inspection findings and resolve deficiencies to the satisfaction of the regulators; (9) actions of regulatory authorities, which may affect the initiation, timing and progress of clinical studies or future regulatory approvals or marketing authorizations; (10) the ability of Alvotech or its partners to enroll and retain patients in clinical studies; (11) the ability of Alvotech or its partners, including Advanz, to gain approval from regulators for planned clinical studies, study plans or sites; (12) the ability of Alvotech's partners to conduct, supervise and monitor existing and potential future clinical studies, which may impact development timelines and plans; (13) Alvotech's ability to obtain and maintain regulatory approval or authorizations of its products, including the timing or likelihood of expansion into additional markets or geographies; (14) the success of Alvotech's current and future collaborations, joint ventures, partnerships or licensing arrangements, including the partnership with Advanz; (15) Alvotech's ability, and that of its commercial partners, including Advanz, to execute their commercialization strategy for approved products; (16) Alvotech's ability to manufacture sufficient commercial supply of its approved products; (17) the outcome of ongoing and future litigation regarding Alvotech's products and product candidates; (18) the potential impact of the ongoing COVID-19 pandemic on the FDA's review timelines, including its ability to complete timely inspection of manufacturing sites; (19) the impact of worsening macroeconomic conditions, including rising inflation and interest rates and general market conditions, war in Ukraine and global geopolitical tension, and the ongoing and evolving COVID-19 pandemic on the Alvotech's business, financial position, strategy and anticipated milestones; and (20) other risks and uncertainties set forth in the sections entitled 'Risk Factors' and 'Cautionary Note Regarding Forward-Looking Statements' in documents that Alvotech may from time to time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed. The recipient agrees that it shall not seek to sue or otherwise hold Alvotech or any of its directors, officers, employees, affiliates, agents, advisors, or representatives liable in any respect for the provision of this communication, the information contained in this communication, or the omission of any information from this communication. Advanz Pharma Forward Looking Statements Certain statements in this press release are forward-looking statements. These statements may be identified by words such as 'anticipate', 'expectation', 'belief', 'estimate', 'plan', 'target', 'project', 'will', 'may', 'should' or 'forecast' and similar expressions, or by their context. Although Advanz Pharma believes that these assumptions were reasonable when made, by their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial consequences of the plans and events described herein. Actual results may differ from those set forth in the forward-looking statements as a result of various factors (including, but not limited to, future global economic conditions, changed market conditions affecting the industry, intense competition in the markets in which Advanz Pharma operates, costs of compliance with applicable laws, regulations and standards, diverse political, legal, economic and other conditions affecting Advanz Pharma's markets, and other factors beyond the control of Advanz Pharma. Neither Advanz Pharma nor any of its directors, officers, employees, advisors, or any other person is under any obligation to update or keep current the information contained in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward-looking statements, which speak of the date of this press release. Statements contained in this press release regarding past trends or events should not be taken as a representation that such trends or events will continue in the future. No obligation is assumed to update any forward-looking statements. The information contained in this press release is provided as at the date of this document and is subject to change without notice. MEDIA CONTACTS Alvotech Global Communications and Investor Relations Benedikt Stefansson [email protected] Advanz Pharma Global Corporate Communications Courtney Baines [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.

Yahoo

an hour ago

• Yahoo

Can Investing $10,000 in Quantum Computing (QUBT) Stock Turn Into $1 Million by 2035?

Quantum Computing would need to deliver a CAGR of roughly 58.49% to turn $10,000 into $1 million by 2035. Explosive growth in the photonic integrated circuit market could help the company achieve this goal. However, the probability that Quantum Computing will be a millionaire-maker in 10 years is still low. 10 stocks we like better than Quantum Computing › Quantum Computing (NASDAQ: QUBT) is an up-and-coming pioneer in the red-hot field of quantum computing. Could investing $10,000 in this stock turn into $1 million by 2035? It's possible, but the odds are stacked against it. That said, I think there is a viable path for Quantum Computing to make you a millionaire over the next 10 years. Here's what would be required. Quantum Computing's market cap currently hovers around $2.66 billion. Its share price was $18.88 at the market close on June 20, 2025. An investment of $10,000 would buy 529 shares at that price, with $12.48 left over. The company's share price would need to grow 100x to $1,888 for a $10,000 initial investment (assuming you didn't buy any fractional shares) to be worth $1 million in a decade. That reflects a compound annual growth rate (CAGR) of roughly 58.49%. Quantum Computing has certainly demonstrated that it can deliver a much greater annual return than that over the short term. Over the last 12 months, the stock has skyrocketed by more than 3,000%. Sustaining a CAGR of 58.49% over 10 years is a daunting task, but it's not impossible. For example, a $10,000 investment in Nvidia in 2015 would be worth over $2.6 million today. Of course, you would have had to resist the temptation to sell during the GPU stock's huge swings up and down during that period. Now for a more difficult question: How could Quantum Computing stock achieve a CAGR of 58.49% over the next 10 years? To answer this question, we need to understand the company's business. Quantum Computing uses integrated photonics (computing with particles of light) and nonlinear quantum optics to develop quantum computers. The company believes its approach to quantum computing is superior to rivals' methods that use superconducting, trapped-ion, and annealing architectures. Photons' advantages include lower energy consumption, faster processing, and scalability. The photonic integrated circuit market size in 2024 was around $15 billion. Over the next five years, this market is projected to expand by a CAGR of 20.5% to $38.4 billion. While that is an impressive growth rate, it isn't enough to propel Quantum Computing stock 100x higher. But Quantum Computing could grow significantly faster than the overall photonic integrated circuit market. The company's thin film lithium niobate wafers, which it believes will be "the silicon of the future," could make it possible. Also, the photonic integrated circuit market's growth could accelerate beyond 2029. I could envision this occurring if the adoption of the technology in areas such as artificial intelligence (AI), autonomous vehicles, and high-performance computing takes off in a huge way. It's quite possible that investing $10,000 in Quantum Computing stock could make you a millionaire over the next 10 years. But how probable is this scenario? The odds aren't great. For one thing, Quantum Computing's photonics technology might be surpassed by approaches that prove to be even better. Many of the companies investing heavily in developing quantum computers have deep pockets, including Google parent Alphabet, Amazon, IBM, Microsoft, and Nvidia. Other rising stars in the quantum computing industry, such as IonQ, D-Wave Quantum, and Rigetti Computing, could potentially be bigger winners than Quantum Computing. Perhaps progress in advancing quantum computing technology won't be fast enough to support the market growth required for Quantum Computing to be a millionaire-maker. I suspect that won't be the case, but I wouldn't rule it out. The good news for investors, though, is that Quantum Computing doesn't have to turn an initial $10,000 into $1 million by 2035 to still deliver exceptional returns. Before you buy stock in Quantum Computing, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Quantum Computing wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool's board of directors. John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Keith Speights has positions in Alphabet, Amazon, and Microsoft. The Motley Fool has positions in and recommends Alphabet, Amazon, International Business Machines, Microsoft, and Nvidia. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. Can Investing $10,000 in Quantum Computing (QUBT) Stock Turn Into $1 Million by 2035? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Yahoo

2 hours ago

• Yahoo

3 of Wall Street's Favorite Stocks Playing with Fire

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it's worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover. Unlike the investment banks, we created StockStory to provide independent analysis that helps you determine which companies are truly worth following. That said, here are three stocks where Wall Street may be overlooking some important risks and some alternatives with better fundamentals. Consensus Price Target: $9.28 (89.8% implied return) Established in 1996, Pangaea Logistics (NASDAQ:PANL) specializes in global logistics and transportation services, focusing on the shipment of dry bulk cargoes. Why Should You Dump PANL? Customers postponed purchases of its products and services this cycle as its revenue declined by 5.5% annually over the last two years Earnings per share have contracted by 33.9% annually over the last three years, a headwind for returns as stock prices often echo long-term EPS performance Free cash flow margin dropped by 9.1 percentage points over the last five years, implying the company became more capital intensive as competition picked up At $4.89 per share, Pangaea trades at 8.9x forward P/E. Read our free research report to see why you should think twice about including PANL in your portfolio, it's free. Consensus Price Target: $2.53 (239% implied return) Founded by two brothers, Purple (NASDAQ:PRPL) creates sleep and home comfort products such as mattresses, pillows, and bedding accessories. Why Are We Out on PRPL? Products and services aren't resonating with the market as its revenue declined by 6.3% annually over the last two years Eroding returns on capital from an already low base indicate that management's recent investments are destroying value Limited cash reserves may force the company to seek unfavorable financing terms that could dilute shareholders Purple is trading at $0.75 per share, or 24.5x forward EV-to-EBITDA. Check out our free in-depth research report to learn more about why PRPL doesn't pass our bar. Consensus Price Target: $31.50 (50.6% implied return) Originally founded in 1983 as the first private prison company in the United States, CoreCivic (NYSE:CXW) operates correctional facilities, detention centers, and residential reentry programs for government agencies across the United States. Why Do We Avoid CXW? Sluggish trends in its average available beds suggest customers aren't adopting its solutions as quickly as the company hoped Earnings per share have dipped by 5.6% annually over the past three years, which is concerning because stock prices follow EPS over the long term Capital intensity has ramped up over the last five years as its free cash flow margin decreased by 10.2 percentage points CoreCivic's stock price of $20.91 implies a valuation ratio of 23x forward P/E. To fully understand why you should be careful with CXW, check out our full research report (it's free). The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today